Role of serum CgA determination for neuroendocrine neoplasma

doi:10.3969/j.issn.1673-8640.2019.02.006

Abstract

Abstract:

Objective To investigate the role of serum chromogranin A（CgA） determination for neuroendocrine neoplasma（NEN）. Methods In 63 patients with NEN（NEN group）,16 patients with gastrointestinal and pancreatic tumors（digestive system tumor group） and 30 healthy subjects（healthy control group） Serum CgA levels and carbohydrate antigen（CA）19-9 levels were determined. The clinicopathological characteristics（sex,age,the primary site of tumors,the grade of tumors and the presence or absence of distant metastasis） of NEN patients were recorded. The efficiency of serum CgA for the diagnosis of NEN was evaluated by receiver operating characteristic（ROC）curve. Results Serum CgA level in NEN group was higher than those in digestive system tumor group and healthy control group（P<0.05）,and there was no statistical significance between digestive system tumor group and healthy control group（P>0.05）. Serum CgA level in NEN patients with distant metastasis was higher than that without distant metastasis（P<0.05）. There was no statistical significance for serum CgA levels in patients with different sex,ages,the primary sites of tumors and the grades of tumors（P>0.05）. ROC curve analysis showed that the area under curve（AUC）of serum CgA in the diagnosis of NEN was 0.989,the optimal cut-off value was 47.31 ng/mL,the sensitivity was 95.5%,and the specificity was 92.3%. Using digestive system tumor group as control,the AUC of serum CgA for the differential diagnosis of NEN was 0.948,the optimal cut-off value was 50.97 ng/mL,the sensitivity was 84.8%,and the specificity was 90.9%. The AUC of serum CgA combined with CA19-9 was 0.956,the sensitivity was 90.5%,and the specificity was 81.8%. Compared with the results of preoperation,serum CgA level decreased in 25 of 32 NEN patients after operation（P<0.05）. There was no statistical significance for serum CgA level before and after operation in the 7 patients（P<0.05）.Conclusions CgA can be used for the assistant diagnosis and therapeutic monitoring of NEN,and it plays a role in predicting tumor metastasis.

Key words: Chromogranin A, Neuroendocrine neoplasma, Enzyme-linked immunosorbent assay

CLC Number:

R446.1

WU Jun, LU Renquan, GUO Lin. Role of serum CgA determination for neuroendocrine neoplasma[J]. Laboratory Medicine, 2019, 34(2): 122-125.

Figures/Tables 3

References 12

[1]	MODLIN I M,GUSTAFSSON B I,MOSS S F,et al.Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease[J]. Ann Surg Oncol,2010,17(9):2427-2443.
[2]	ARDILL J E,ERIKKSON B.The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut[J]. Endocr Relat Cancer,2003,10(4): 459-462.
[3]	李宁宁,白春梅. 胃肠胰腺神经内分泌肿瘤治疗进展[J]. 癌症进展,2010,8(4): 352-356.
[4]	何英武. 糖化血红蛋白测定的研究新进展[J]. 当代医学(学术版),2008,2(7):58-59.
[5]	中国临床肿瘤学会神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J]. 临床肿瘤学杂志,2016,21(10):927-946.
[6]	LOUTHAN O.Chromogranin a in physiology and oncology[J]. Folia Biol(Praha),2011,57(5): 173-181.
[7]	PHAN A T,KUNZ P L,REIDY-LAGUNES D L. New and emerging treatment options for gastroenteropancreatic neuroendocrine tumors[J]. Clin Adv Hematol Oncol,2015,13(5 Suppl 5):1-18.
[8]	MOLINA R,ALVAREZ E,ANIEL-QUIROGA A,et al.Evaluation of chromogranin A determined by three different procedures in patients with benign diseases,neuroendocrine tumors and other malignancies[J]. Tumour Biol,2011,32(1): 13-22.
[9]	GLINICKI P,KAPUSCINSKA R,JESKE W.The differences in chromogranin A(CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods[J]. Endokrynol Pol,2010,61(4): 346-350.
[10]	胡玉懿,吴蕙,韩序,等. ELISA双抗体夹心法检测嗜铬蛋白A的性能评价及临床应用[J]. 检验医学,2018,33(1):55-59.
[11]	徐建明,汤晨. 胃肠胰腺神经内分泌肿瘤国际诊断共识的解读[J]. 临床肿瘤学杂志,2011,16(11):1033-1038.
[12]	谢宗圆,李海旺,何世宏. 血浆嗜铬粒蛋白A对胃肠胰腺内分泌肿瘤的诊断价值[J]. 内蒙古医学杂志,2014,46(1): 82-83.

病理特征	例数	CgA
性别
男	36	98.43（67.99~196.18）
女	27	96.46（65.02~233.67）
年龄（岁）
≥50	34	99.72（68.69~236.72）
<50	29	92.83（66.02~214.98）
原发肿瘤部位
胃肠道	10	87.63（54.73~235.07）
胰腺	53	97.60（66.64~198.99）
肿瘤分级
G1级	23	61.09（60.85~306.29）
G2级	29	138.54（56.55~201.62）
G3级	7	66.57（23.5~267.36）
远处转移
有	22	166.30（113.06~237.92）
无	18	98.43（56.84~194.58）^*

病理特征	例数	CgA
性别
男	36	98.43（67.99~196.18）
女	27	96.46（65.02~233.67）
年龄（岁）
≥50	34	99.72（68.69~236.72）
<50	29	92.83（66.02~214.98）
原发肿瘤部位
胃肠道	10	87.63（54.73~235.07）
胰腺	53	97.60（66.64~198.99）
肿瘤分级
G1级	23	61.09（60.85~306.29）
G2级	29	138.54（56.55~201.62）
G3级	7	66.57（23.5~267.36）
远处转移
有	22	166.30（113.06~237.92）
无	18	98.43（56.84~194.58）^*

[1]	XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results [J]. Laboratory Medicine, 2023, 38(4): 352-356.
[2]	HU Yan, SHEN Ge, LI Qiong, ZENG Ziyan, , YANG Gang, LI Ping, CHEN Yufeng, ZHANG Zhen, XIE Xiaobing. Roles of 2 SARS-CoV-2 antibody assays in the diagnosis of corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(12): 1294-1297.
[3]	YE Zhenxuan, YANG Biwei, ZHOU Wenjing, LIU Qiang, LI Hongmei, ZHANG Haiyan, REN Zhijing, ZHANG Hua. Screening of specific anti-mitochondrial antibody-M2 in 36 459 healthy subjects in Guiyang [J]. Laboratory Medicine, 2018, 33(3): 205-208.
[4]	ZHAO Yinxia, OU Meixian, QU Yi, LU Youli, ZHANG Meiwei, LI Shuijun. Determination of human serum ouabain by UPLC-MS/MS and methodology comparison [J]. Laboratory Medicine, 2018, 33(11): 1013-1016.
[5]	QI Yingjie, SHI Yuru, LIU Ting, YUE Li, ZHAO Changcheng, WANG Yun, MA Xiaoling. Establishment and preliminary application of optimal cut-off value of anti-multi-epitope fusion antigen IgG antibody of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2018, 33(10): 899-902.
[6]	HU Yuyi, WU Hui, HAN Xu, ZHANG Chunyan, GUO Wei, LOU Wenhui, PAN Baishen. Performance of double-antibody sandwich ELISA for chromogranin A determination [J]. Laboratory Medicine, 2018, 33(1): 55-59.
[7]	XIE Liangcai, FAN Wen, XU Lei, XU Rong, LIU Tianchun. False negative interference of RF on serum HBeAg by ELISA [J]. Laboratory Medicine, 2017, 32(9): 765-768.
[8]	LING Yingchun, ZHOU Yueqin, DUAN Di, HU Lingmin. Determination of central nervous system specific protein for senile dementia [J]. Laboratory Medicine, 2017, 32(11): 1021-1023.
[9]	YAN Jun, YANG Wei, ZHAI Shuanzhu, XUE Zhixin, YU Peng, ZHOU Zeqi. Preparation of polyclonal antibody and development of a competitive ELISA for fungal (1,3)-beta-D-glucan [J]. Laboratory Medicine, 2015, 30(9): 931-933.
[10]	SUN Lishan, WANG Mingdong, LU Liu, LIU Yingbing, LU Lin, GUO Jinhu, FAN Lieying. Establishment of an ELISA for the quantitative measuring of glucagon-like peptide 1 and the primary clinical application [J]. Laboratory Medicine, 2015, 30(8): 835-840.
[11]	MENG Cunren, TANG Jing, ZHANG Zhaoxia.. Analysis on repeatability and diagnostic threshold value of 2 ELISA systems for anti-HCV antibody determination [J]. Laboratory Medicine, 2015, 30(12): 1175-1180.
[12]	ZHANG Haiping, YAN Huiping, ZHANG Xin, ZHAO Dantong, MA Yinxue, SUN Limei, LI Zhuomin.. Automatic ELISA system for the detection of anti-mitochondrial M2 antibody and its clinical significance [J]. Laboratory Medicine, 2015, 30(12): 1234-1237.
[13]	TANG Jing, BAO Jianling, MENG Cunren, ZHANG Zhaoxia. Confirmation and analysis of the cut-off value in hepatitis C antibody determined by ELISA with receiver operating characteristic curve [J]. , 2014, 29(8): 826-830.
[14]	YU Hong，ZHU Wei，CUI Yangyang，QUE Jinya. The investigation of the retesting range of the TPAb sample detected by ELISA [J]. , 2013, 28(4): 312-314.
[15]	XIAO Jinhua，ZHU Huayan，WANG Yaping，PAN Yuhong，HUANG Xuan. Detection of peripheral blood high mobility group protein box-1 in patients with gastric cancer and its clinical significance [J]. , 2013, 28(4): 301-304.